|
OIG: HHS Must Clamp Down on Off-Label Drug Promotion
Drugmakers could see a more forceful crackdown on off-label promotion, says a new Office of Inspector General (OIG) report that directs HHS to focus on the practice.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives